Theratechnologies (NSDQ:THTX) announced that the peer-reviewed journal Cancer Science had published its preclinical research related to TH1902, a peptide linked to the chemotherapeutic agent docetaxel.
The research tested the investigational drug as a sortilin-positive triple-negative breast cancer (TNBC) treatment. TNBC lacks the expression or amplification of targetable biomarker. The prognosis for this cancer subgroup tends to be worse than other forms of breast cancer.
The study supported the safety and efficacy of TH1902 against TNBC by way of a SORT1 receptor-mediated mechanism. Furthermore, the investigators confirmed that high expression of the SORT1 receptor was linked to diminished survival rates among TNBC patients.
The paper concluded that “the docetaxel-TH19P01 conjugate (TH1902) exerted potent antiproliferative and antimigratory activities when tested on TNBC-derived MDA-MB-231 cells.”
The article is titled “TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.”
The company is also developing the drug tesamorelin as a treatment of nonalcoholic steatohepatitis (NASH).
Filed Under: clinical trials, Drug Discovery, Oncology
